Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Luspatercept

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 1Alliance revenue - Reblozyl

    02 5Reblozyl

    03 2Reblozyl

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Reblozyl

    Luspatercept-aamt

    arrow
    IOPC
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept-aamt

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 274

    2019 Revenue in Millions : 0

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Reblozyl

    Luspatercept-aamt

    arrow
    IOPC
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept-aamt

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 551

    2020 Revenue in Millions : 274

    Growth (%) : 101

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Reblozyl

    Luspatercept-aamt

    arrow
    IOPC
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept-aamt

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 717

    2021 Revenue in Millions : 551

    Growth (%) : 30

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Reblozyl

    Luspatercept

    arrow
    IOPC
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Merck & Co.

    Luspatercept

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 166

    2021 Revenue in Millions : 17

    Growth (%) : 876

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Reblozyl

    Luspatercept-aamt

    arrow
    IOPC
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept-aamt

    Main Therapeutic Indication : Hematology

    Currency : USD

    2023 Revenue in Millions : 1,008

    2022 Revenue in Millions : 717

    Growth (%) : 41

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Reblozyl

    Luspatercept

    arrow
    IOPC
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Merck & Co.

    Luspatercept

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 212

    2022 Revenue in Millions : 166

    Growth (%) : 28

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Alliance revenue - Reblozyl

    Luspatercept

    arrow
    IOPC
    Not Confirmed

    Brand Name : Alliance revenue - Reblozyl

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Merck & Co.

    Luspatercept

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 371

    2023 Revenue in Millions : 212

    Growth (%) : 75

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Reblozyl

    Luspatercept

    arrow
    IOPC
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept

    Main Therapeutic Indication : Hematology

    Currency : USD

    2024 Revenue in Millions : 1,773

    2023 Revenue in Millions : 1,008

    Growth (%) : 76

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF